Page last updated: 2024-12-07
n-(n-butyl) thiophosphoric triamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 93502 |
| CHEMBL ID | 3186430 |
| SCHEMBL ID | 180545 |
| MeSH ID | M0307136 |
Synonyms (37)
| Synonym |
|---|
| 94317-64-3 |
| n-butylphosphorothioic triamide |
| n-diaminophosphinothioylbutan-1-amine |
| A844914 |
| n-diaminophosphinothioylbutan-1-amine;n-(n-butyl)thiophosphorictriamide |
| n-(n-butyl)thiophosphoric triamide |
| dtxsid4044747 , |
| dtxcid2024747 |
| cas-94317-64-3 |
| NCGC00256311-01 |
| tox21_302015 |
| AKOS006230585 |
| a6103ok7gf , |
| unii-a6103ok7gf |
| phosphorothioic triamide, butyl- |
| phosphorothioic triamide, n-butyl- |
| FT-0629302 |
| agrotain |
| n-butylphosphorothioic triamide [mi] |
| SCHEMBL180545 |
| mfcd00269941 |
| Q-201452 |
| n-butylthiophosphoric triamide |
| B5873 |
| CHEMBL3186430 |
| n-(n-butyl)thiophosphoric triamide, analytical standard |
| n-(n-butyl) thiophosphoric triamide |
| n-(n-butyl)thiophosphorictriamide |
| BCP05323 |
| AS-15132 |
| agrotain dc; agrotain plus; agrotain prime; agrotain ultra; armu; n-butylthiophosphoric triamide |
| Q27273672 |
| n-(n-butyl)thiophosphoramide |
| HY-107199 |
| CS-0027607 |
| EN300-345781 |
| butyl[diamino(sulfanylidene)-lambda5-phosphanyl]amine |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, there are few case studies about reduced N application combined with double inhibitors (DIs, NI plus UI), especially under drip irrigation systems." | ( A 2-year study of the impact of reduced nitrogen application combined with double inhibitors on soil nitrogen transformation and wheat productivity under drip irrigation. Chu, G; Hu, B; Li, J; Shah, JA; Tao, R, 2021) | 0.62 |
| "Cutting the N application rate by 20% combined with NBPT and nitrapyrin could provide a sustainable fertilization strategy for wheat production under drip irrigation." | ( A 2-year study of the impact of reduced nitrogen application combined with double inhibitors on soil nitrogen transformation and wheat productivity under drip irrigation. Chu, G; Hu, B; Li, J; Shah, JA; Tao, R, 2021) | 0.62 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% of initial BW and dosed with either 0 (control), ." | ( Influence of the novel urease inhibitor N-(n-butyl) thiophosphoric triamide on ruminant nitrogen metabolism: II. Ruminal nitrogen metabolism, diet digestibility, and nitrogen balance in lambs. Axe, DE; Harmon, DL; Huntington, GB; Larson, BT; Ludden, PA, 2000) | 0.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 13.6854 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 61.6448 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 60.6660 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.3953 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 2.7536 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 30.6379 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 25 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||